Sclerotherapy in Pyogenic Granuloma: An Open Uncontrolled Trial

Pyogenic granuloma (PG) is a common, benign lesion of vascular origin. It may rapidly grow in response to an unknown stimulus that triggers endothelial proliferation. The treatment of PG using sclerosing agents is a novel approach to overcome drawbacks associated with other procedures. The crucial purpose of this study is to evaluate the efficacy and safety of detergent sclerosant, sodium tetradecyl sulphate (STS) in the management of PG. A total of 18 patients with PG, attending dermatology venereology and leprosy (DVL) outpatient department (OPD) were treated with sclerotherapy after obtaining written and informed consent. STS solution (3%, 30 mg/mL) was injected with insulin syringe slowly into the lesion until the lesion blanched up to maximum amount of 0.3 mL. Injection was repeated every week until resolution or up to maximum of 4 doses. Follow-up evaluation was performed monthly, up to 3 months. In our study, complete resolution was seen in all the patients. No complication occurred after injection. All the patients were followed up for 3 months and none of the lesions recurred over this duration. Sclerotherapy is effective and safe in the treatment of PG without any recurrence. This approach may become a first-line therapy option for PG, especially in cases of recurrent PG associated with bleeding, and in lesions over surgically inaccessible areas.